Boron — Body Handbook

Supplements · §486

Boron

You eat about a milligram of boron a day — from coffee, raisins, avocados, the water you drink — and the evidence suggests that's on the low side. Push it to three to ten milligrams a day and the trials point the same way across four different systems: calcium stops washing out of your urine, achy joints settle down, sex hormones drift in a more youthful direction, and inflammation markers fall. None of it dramatic. All of it real. Trial sizes are small, the cost is trivial, and EFSA still won't call it essential.

Do · Daily Evidence Emerging Chapter Supplements

A capsule that costs less than your morning coffee, with the strongest case for people with achy knees or hips and women heading into menopause. In the trials, joint pain softens within weeks, calcium and magnesium stop leaving the body as fast, and inflammation markers drift down inside a week. The effect on free testosterone in men is real but small — small enough that you should not buy this as a testosterone booster. Honest framing: a low-cost, low-risk hedge against four slow-moving problems, not a substance that turns heads.

Boron's main move in the body is binding. It slides into the matching pairs of hydroxyl groups on hormones, vitamins, and proteins — like a clip onto two adjacent rings — and slows down the enzymes that would otherwise pull those molecules apart Pizzorno 2015. The result is that the active form of vitamin D, of estrogen, of testosterone — the stuff your body has already made — sticks around longer Nielsen 2014.

That same chemistry hangs onto calcium and magnesium. It also gums up the enzymes that drive inflammation — a related mechanism is the basis for the chemotherapy drug bortezomib, which is built around a boron atom Pizzorno 2015. So a single small molecule nudges four different systems at once: bones hold onto more of their minerals, joints get a quieter signalling environment, sex hormones don't get broken down quite as fast, and the inflammatory baseline drifts down.

The catch is that nobody has pinned down a single enzyme that needs boron the way an iron-dependent enzyme needs iron. That is why EFSA still classifies it as non-essential — it has functions, but no proven requirement. The effect is best read as a modulator: it doesn't add a new pathway, it nudges several existing ones in a favourable direction.

What the trials actually show

Four threads run through the human literature, and they point the same way. The trials are small. The directions are consistent.

Bones. The foundational study put twelve postmenopausal women on a low-boron diet for four months, then gave them three milligrams a day. Calcium and magnesium losses in their urine dropped sharply. Their estrogen and testosterone roughly doubled — and the bone effect was largest in women who were also short on magnesium Nielsen et al. 1987. A six-month follow-up with the same dose confirmed the calcium-retention pattern Hunt et al. 1997.

Joints. Twenty people with osteoarthritis took six milligrams a day or placebo for eight weeks. Seventy-one percent of completers on boron improved; ten percent on placebo did Travers et al. 1990. Later trials with a fruit-derived form of boron, calcium fructoborate, showed similar arthritis-pain improvements alongside a roughly one-third drop in C-reactive protein within two weeks Scorei et al. 2011 Reyes-Izquierdo et al. 2012.

The hormone study above is the most-quoted result on the internet, and it deserves a sober read: eight men, one week, no replication. The direction is consistent with the mechanism. The size of the effect, and whether it persists beyond a week, is not yet settled.

The brain. When healthy adults are kept on diets supplying only a quarter milligram of boron a day — about a fifth of what most people eat — brain electrical activity slows toward a pattern seen in malnutrition, and they get worse at attention, hand-eye coordination, and short-term-memory tasks. Restoring boron to roughly three milligrams a day reverses it Penland 1994 Penland 1998. This is a recovery effect, not an enhancement — supplementing past your normal intake does not make you sharper. But it does mean a low-fruit, low-vegetable eater may be running with a small handicap they would not otherwise notice.

What "low boron" looks like over decades

Most readers will not feel a dramatic absence of boron, because most adults eat between one and two milligrams a day, and the body is forgiving at the low end. The story is slower than that.

If you skip the fruit, the nuts, the avocados, and the coffee, you trend toward the bottom of the range — closer to half a milligram. Over a decade or two, the typical pattern in the literature is the same things that look like ordinary aging: knees that complain on the second flight of stairs, hips that stiffen up before you get out of the car, a bone-density scan that comes back worse than your sister's, an inflammatory baseline that runs a little hotter than it should Pizzorno 2015. None of that is caused by low boron in any provable single-cause sense. It is one of several small contributing factors the literature can name.

For women heading into menopause, the foundational data is more pointed: calcium leaves the body faster on low-boron, low-magnesium intake, and one of the cheapest mineral hedges against that loss is the milligram of boron in a handful of dried apricots Nielsen et al. 1987 Hunt et al. 1997. For men, an NHANES analysis found prostate-cancer risk was about half as high in those eating above 1.5 mg/day compared to those at 0.9 mg/day or below — suggestive, not settled, and not replicated in every cohort Cui et al. 2004. None of it is a single big lever. All of it adds up.

How to take it

The trial-effective range is three to ten milligrams a day, taken once, with breakfast. Three milligrams is the bone-and-mineral dose from the foundational study; six is the arthritis-trial dose; ten is the hormone-and-inflammation dose Nielsen et al. 1987 Travers et al. 1990 Naghii et al. 2011. All three sit at or below the European safety ceiling of ten milligrams a day for adults EFSA 2004.

When not to take it

For everyone else, the safety margin at 3–10 mg/day is large. Acute toxicity does not appear until single doses above 100 mg; a long-running population study in a high-boron Turkish region whose drinking water averaged 10 mg/L showed no excess health problems over 36 years Pizzorno 2015.

What the marketing gets wrong

"Natural testosterone booster." The Naghii study is the source of the famous 28% free-testosterone number, and it deserves the asterisk: eight men, one week, total testosterone barely moved Naghii et al. 2011. The change was in the free fraction, which is real but a small absolute lift. If your testosterone is low enough to bother a doctor, boron is not the answer; if it is normal and you feel fine, boron is a small nudge in a direction you may not notice.

"Borax is industrial, glycinate is safe." The clinical studies were almost all done with sodium tetraborate — borax. That is the molecule the trials proved. Boron glycinate and citrate are perfectly fine, but they are not safer or more bioavailable; they are just easier to sell Nielsen 2014.

"It's an essential nutrient." Not formally. European regulators classify boron as non-essential and set no minimum daily requirement EFSA 2004. What it has is a body of evidence for functional benefit at typical dietary intakes — which is a different claim. Honest framing: a bioactive trace element with consistent benefit at the doses tested, not a vitamin you'll otherwise go deficient in.

Why it sometimes "doesn't work"

Three common reasons the personal experiment falls flat.

You already eat enough. A handful of raisins, two avocados, a few cups of coffee, and a glass of red wine takes you past 2 mg/day on their own. If you are already on the plateau of the dose-response curve, a supplement does very little. The strongest responders in the literature are people whose habitual intake was below 1 mg/day Pizzorno 2015.
You took the multivitamin dose. Most multivitamins include 150 micrograms to 1 milligram of boron — below the range any of the trials used. The studied effects start at 3 mg/day.
You stopped after a week. Inflammation markers shift within days, but the joint and bone effects in the trials took 2–8 weeks. Give a course at least six weeks before deciding.

What you'd actually notice

The first week. Nothing, mostly. Your blood-test numbers would be different — hs-CRP and TNF-α drift down within days in the trials — but you cannot feel a CRP number Naghii et al. 2011.

The first month or two. If you started with achy knees or hips, this is the window where about half the people in the arthritis trials noticed the morning stiffness easing — getting out of the car stops being an event, the second flight of stairs stops announcing itself Travers et al. 1990 Reyes-Izquierdo et al. 2012. The other half noticed nothing. If you did not have aching joints to begin with, you would not notice this layer at all.

The first year, and beyond. The slow part. Calcium and magnesium are leaving the body a little less aggressively, which on a DXA bone-density scan shows up as a number that did not get worse as quickly as the trajectory predicted Nielsen et al. 1987 Hunt et al. 1997. The face that holds its shape into the seventies and eighties is in part the face whose underlying jaw and cheekbones did not lose their density — boron is one small contribution to that, not the whole story Pizzorno 2015. The honest framing: this is not a substance that changes how you feel today. It is a small, cheap hedge against several slow-moving losses that compound over decades.

Worth knowing alongside this

Boron does not act alone. The minerals it interacts with — and the routines that move the same dials — are worth keeping in view:

Magnesium. The bone and hormone effects in the foundational study were biggest in women whose magnesium was also low. The two work together.
Vitamin D. Boron extends the half-life of active vitamin D; vitamin D status sets the ceiling on what boron can do for your bones.
Resistance training. The single highest-impact intervention for bone density. Boron is a hedge; lifting things is the actual answer.
The Mediterranean-style diet. Coffee, raisins, avocados, nuts, legumes, leafy greens, red wine — the foods that get you to a boron-sufficient intake without a capsule, and pull on a half-dozen other levers at the same time.

Related in the handbook

Helps

— Boron slows the calcium you lose in urine, a small nudge toward holding onto bone — useful alongside the real osteoporosis basics.

Alternatives

— For achy joints, boron is one low-cost option; curcumin is another with its own evidence.
— Tongkat ali is the other modest hormone nudge in this lane: small effects, mostly in men whose levels already slipped.

— Boron helps the body hold onto magnesium and calcium rather than washing them out.
— Boron nudges free testosterone a little — but it's no booster; if T is the question, get tested.

1. Substance + claimed effects

Boron is an ultratrace element ingested as boric acid or borate from fruits, leafy greens, nuts, legumes, coffee, wine, and drinking water; typical Western dietary intake runs 1–2 mg/day, with intake in boron-rich regions reaching 8–10 mg/day Pizzorno 2015. Supplemental forms include sodium tetraborate, boric acid, boron citrate / aspartate / glycinate chelates, and the patented sugar-borate ester calcium fructoborate (FruiteX-B). The entry covers boron supplementation at the conventional 3–10 mg/day range and its four documented consequence clusters: (1) bone mineral metabolism — calcium / magnesium / phosphorus retention and bone-formation signalling; (2) joint health — symptom relief in osteoarthritis and rheumatoid arthritis; (3) sex-steroid regulation — free testosterone, estradiol, dihydrotestosterone, sex hormone binding globulin (SHBG), and vitamin D; (4) systemic inflammation — high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α); plus a secondary cluster on (5) brain electrical activity and cognitive performance under deprivation-repletion conditions. EFSA classifies boron as non-essential with a tolerable upper intake level of 10 mg/day for adults EFSA 2004; the IOM sets the UL at 20 mg/day. No human deficiency syndrome is formally defined.

2. Evidence by addressing question

mechanism

Science. Boron's biochemistry is dominated by its capacity to form reversible covalent ester bonds with cis-hydroxyl groups on biomolecules: ribose moieties of NAD⁺/SAM, serine-protease active sites, and hydroxylated steroids and vitamin D metabolites Pizzorno 2015 Nielsen 2014. Three mechanism families carry most of the entry's claims:

Steroid-hormone half-life extension. Boron inhibits 24-hydroxylase activity, slowing the catabolism of 17β-estradiol, testosterone, and 25(OH)D₃, plausibly explaining the observed rises in circulating free hormone after supplementation Pizzorno 2015 Devirian & Volpe 2003.
Serine-protease inhibition. Boric acid binds the catalytic serine of trypsin-fold proteases (PSA, chymotrypsin, plasmin) and proteasome subunits — the same mechanism exploited therapeutically by bortezomib (Velcade) in multiple myeloma Pizzorno 2015.
Mineral metabolism. Boron reduces urinary calcium and magnesium excretion, enhances 25(OH)D₃ serum concentration when vitamin D status is suboptimal, and amplifies the activity of osteoblast-relevant enzymes — collectively shifting bone toward net deposition under stress conditions Nielsen et al. 1987 Hunt et al. 1997.

Mechanism notes. No specific boron-dependent enzyme has been identified in humans — a key reason EFSA declines to classify it as essential EFSA 2004. The activity is best modelled as modulatory: boron acts as a cofactor of cofactors, shifting equilibria of pre-existing pathways rather than catalyzing a unique step.

evidence

Bone & mineral metabolism. The foundational Grand Forks metabolic-ward study fed 12 postmenopausal women a low-boron diet (0.25 mg/day) for 119 days, then supplemented 3 mg/day for 48 days. Boron supplementation reduced urinary calcium excretion by ~44% and urinary magnesium loss; serum 17β-estradiol roughly doubled and serum testosterone nearly doubled, most prominently when magnesium intake was also low Nielsen et al. 1987. The 1997 follow-up extended observations across six 24-day periods and confirmed altered calcium / magnesium absorption-retention dynamics with 3 mg/day boron Hunt et al. 1997. No long-term DXA-endpoint RCT in humans exists.

Joint health — osteoarthritis. Travers et al. (1990) randomised 20 patients with symptomatic osteoarthritis to 6 mg/day boron (as sodium tetraborate) vs placebo for 8 weeks. Among completers, 71% on boron improved subjectively vs 10% on placebo; pilot-grade evidence, small n, no imaging endpoint Travers et al. 1990. Calcium fructoborate trials (n = 60–116) report 30–50% reductions in WOMAC pain and stiffness scores at 14 days alongside ~37% drops in hs-CRP Reyes-Izquierdo et al. 2012 Scorei et al. 2011. Both calcium-fructoborate studies were funded by the patent holder (FutureCeuticals / VDF); independent replication is thin.

Sex hormones — males. Naghii et al. (2011) supplemented eight healthy men aged 29–50 with 10 mg/day sodium tetraborate for one week. Free testosterone rose 28% (11.83 → 15.18 pg/mL, p = 0.02); estradiol fell 39% (42.33 → 25.81 pg/mL, p = 0.01); SHBG fell ~5%; hs-CRP and TNF-α fell significantly within six hours of the first dose Naghii et al. 2011. Total testosterone change was non-significant; the free-hormone delta is the load-bearing finding. Sample size is the principal weakness; no replication in a larger cohort has been published.

Inflammation. Naghii's eight-man cohort showed ~20% reductions in TNF-α (12.32 → 9.97 pg/mL) and ~50% reductions in hs-CRP within a week of 10 mg/day boron Naghii et al. 2011. Scorei's 60-subject osteoarthritis trial showed similar hs-CRP reductions with 6 mg/day boron-equivalent from calcium fructoborate Scorei et al. 2011. The signal is small-trial / short-duration; CRP rebound after cessation has not been characterised.

Cognition. Penland's USDA depletion-repletion studies in healthy adults compared diets supplying ~0.25 mg vs ~3.25 mg boron per 2000 kcal/day. Low-boron diets shifted EEG spectral power toward low-frequency activity (a pattern seen in malnutrition and heavy-metal toxicity) and impaired performance on tasks of attention, manual dexterity, eye-hand coordination, and short-term memory Penland 1994 Penland 1998. The cognitive effect is a repletion finding — boron-deprived subjects recover when boron is restored to typical dietary levels; the studies do not establish that supplementing above habitual intake further improves cognition.

Cancer epidemiology (orthogonal to scoring). NHANES III analysis showed a 52% lower prostate-cancer risk in men whose intake exceeded ~1.5 mg/day vs ≤0.9 mg/day (adjusted OR 0.46, 95% CI 0.21–0.98) Cui et al. 2004. Mechanistic plausibility via serine-protease (PSA) inhibition and steroid-modulation. The VITAL cohort (n=35,244) failed to replicate. Ecological data from boron-rich regions show lower cervical and prostate cancer incidence Pizzorno 2015. This is suggestive, not actionable at the supplementation level — covered in the article only as supporting context.

protocol

Dose. Across the trials, three doses recur: 3 mg/day (Nielsen 1987, the dietary-repletion dose), 6 mg/day (Travers arthritis trial, Scorei calcium fructoborate), and 10 mg/day (Naghii hormone study, Pizzorno's review recommendation for osteoporosis / osteopenia / OA contexts) Nielsen et al. 1987 Travers et al. 1990 Naghii et al. 2011 Pizzorno 2015. All sit at or below the EFSA UL of 10 mg/day EFSA 2004.

Form. Sodium tetraborate decahydrate (borax-derived, used in most trials), boric acid, boron citrate / aspartate / glycinate, and calcium fructoborate. Bioavailability of inorganic forms is >90% — boron is absorbed nearly completely as boric acid and excreted via urine within 24–96 hours Nielsen 2014. Organic chelates do not meaningfully outperform inorganic forms on plasma boron, though calcium fructoborate is the form used in most arthritis RCTs.

Timing. Single morning dose with breakfast is sufficient (Naghii protocol). No empirical advantage to split dosing has been demonstrated; plasma half-life is ~21 hours.

Duration. Hormonal and inflammatory responses are detectable within hours to one week. Bone-mineral effects accumulate over weeks. Arthritis symptom response in the trials emerged within 2–8 weeks.

contraindications

Established. Pregnancy and pre-conception: animal studies show developmental toxicity at high boron doses (NOAEL 9.6 mg/kg/day in rats), and the EFSA UL of 10 mg/day is set conservatively against this endpoint EFSA 2004. Hormone-sensitive cancers (estrogen-receptor-positive breast cancer, advanced prostate cancer under androgen-deprivation therapy): the documented rise in free testosterone and the boron-driven extension of estradiol half-life are theoretically problematic, though no clinical harm has been demonstrated Nielsen et al. 1987 Naghii et al. 2011. Renal impairment: boron is renally excreted, and elimination is impaired in advanced CKD.

Toxicity threshold. Acute toxicity emerges at single doses >100 mg (nausea, vomiting, diarrhea, dermatitis); lethal dose in adults is 15–20 g. The therapeutic-to-toxic ratio at 3–10 mg/day is large. A 36-year cohort of 66 men living in a high-boron Turkish region with mean drinking-water boron of 10.2 mg/L (calculated daily intake ~6.8 mg) showed no adverse health effects Pizzorno 2015.

misconceptions

"Boron is a natural testosterone booster like TRT." The free-testosterone increase in the Naghii cohort was statistically significant but absolute changes are modest (a few pg/mL on a base of ~12 pg/mL), and total testosterone barely moved Naghii et al. 2011. Boron is not a replacement for hypogonadism therapy; it nudges steroid-hormone metabolism rather than driving production.
"Borax is just industrial-grade boron and unsafe." Sodium tetraborate decahydrate (borax) was the form used in the Travers arthritis trial, the Nielsen 1987 hormone study, and the Naghii study — and is the form most clinical research is built on Travers et al. 1990 Nielsen et al. 1987. Commercial supplements often use boron citrate / glycinate for marketing reasons, not bioavailability advantages.
"Boron is essential." EFSA explicitly classifies boron as non-essential and has not set a Dietary Reference Value EFSA 2004. The "essentiality" claim rests on functional benefit, not deficiency syndromes. Honest framing: bioactive trace element with consistent benefit at typical intakes, not a required nutrient.
"There's a recognised RDA." No RDA. Various sources cite a "suggested adequate intake" of 1–3 mg/day; these are review-author opinions, not regulatory positions.

audience

Strongest signal: postmenopausal women with low magnesium intake (bone mineral retention, hormone metabolism) Nielsen et al. 1987; middle-aged adults with osteoarthritis (joint symptom relief) Travers et al. 1990 Reyes-Izquierdo et al. 2012; men with low-normal free testosterone (modest free-T modulation) Naghii et al. 2011; populations in low-boron geographic regions where habitual intake is <1 mg/day. Weaker signal: younger adults with adequate dietary boron from fruits/vegetables/coffee/wine, who likely sit near the plateau of the dose-response curve.

alternatives

For each consequence cluster, the catalogue's higher-evidence alternatives:

Bone density: resistance training, vitamin D + calcium adequacy, bisphosphonates in osteoporosis, magnesium. Boron is additive, not substitutive.
Joint symptoms: NSAIDs, glucosamine + chondroitin (modest), exercise, weight management, intra-articular injections. Boron is a low-risk adjunct.
Testosterone: resistance training, sleep extension, body-fat reduction, zinc adequacy, TRT under clinician supervision. Boron's effect size is small relative to any of these.
Inflammation: omega-3, exercise, weight loss, sleep, Mediterranean diet. Boron's CRP/TNF-α signal is comparable in size but from much smaller trials.

failure-modes

Most "boron didn't work" reports trace to (1) already-adequate dietary intake (someone eating fruit, nuts, and drinking coffee gets 1.5–3 mg/day at baseline — supplementation above this plateau is unlikely to add much) and (2) dosing below the trial-effective range (1 mg/day "multivitamin level" doses are below the 3–10 mg range where effects are documented). Confounding by magnesium status: the bone and hormonal effects in Nielsen's data were larger under low-magnesium conditions Nielsen et al. 1987. Brief supplementation periods (<2 weeks) miss the joint-symptom response window.

practicalities

Cost: $8–25/year at 5–10 mg/day from bulk borax or boron-citrate capsules; calcium fructoborate (branded FruiteX-B in joint-health products) runs $80–150/year. Available over-the-counter in all major markets; no prescription required. Shelf-stable, no refrigeration. Mixes well with morning routines. No taste objection (capsules); borax dissolved in water has a mild alkaline taste.

stakes

For the typical reader who falls below the ~1 mg/day intake threshold associated with the population effects (Cui's prostate-cancer signal), the literature suggests slow accumulation of (a) less efficient calcium retention through perimenopause, (b) higher SHBG and lower free testosterone trajectories in men over decades, and (c) higher baseline inflammatory tone Cui et al. 2004 Pizzorno 2015. None of these are dramatic single-event harms — the felt experience is the gradual stiffness, the morning joint complaint, the steadily creeping bone-density loss visible only on DXA.

payoff

Weeks: arthritis symptom response if present (Travers / Scorei trials), shifts in inflammatory markers within days–week (Naghii). Months: continued bone-mineral retention; in men, persistent free-T / estradiol shift if maintained. Years: the population-level signals — fewer fragility fractures in postmenopausal cohorts, reduced age-related joint discomfort — sit at the boundary of what observational data can support, not what individual supplementation has proven. The payoff is real but modest; this is not a substance that transforms a baseline.

history

Boron's biological role was first proposed by Warington (1923) in plants. Human nutritional interest dates to Rex Newnham's clinical observation in the 1960s–80s that joint pain remitted with boron supplementation, leading to the Travers et al. (1990) pilot RCT Travers et al. 1990. The mechanistic foundation was built at the USDA's Grand Forks Human Nutrition Research Center (Nielsen, Hunt, Penland) through the 1980s and 1990s Nielsen et al. 1987 Penland 1998 Hunt et al. 1997. EFSA's 2004 UL opinion is the current regulatory anchor EFSA 2004.

out-of-scope

Boron-based pharmaceuticals (bortezomib, tavaborole) sit outside the trace-mineral supplement scope. Boron neutron capture therapy (oncology) is a different topic. Industrial / occupational boron exposure (workers in mining and glass manufacturing) is a toxicology question, not a supplementation question.

3. The credibility range

Optimist case

Boron is one of the most-overlooked low-cost, low-risk supplements with consistent across-trial signals on bone metabolism, joint symptom relief, sex-steroid modulation, and inflammation. The mechanism is biochemically coherent (cis-diol ester formation explains the steroid-extension and serine-protease effects). Population-level epidemiology corroborates: high-boron regions show lower osteoarthritis, lower prostate cancer, lower cervical cancer Cui et al. 2004 Pizzorno 2015. Cost is trivial ($10–20/year), the EFSA UL gives a 3× safety margin on the highest commonly used dose, and a 36-year high-exposure population shows no harm. The reason there's no Cochrane review is that nobody patents borax — there is no financial incentive for the large-scale RCT that would settle the question. Functional-medicine practitioners (Pizzorno, Newnham) treating real patients have integrated boron for decades.

Skeptic case

The hormonal-effect literature rests on n = 8 (Naghii) and n = 12 (Nielsen) studies in tightly controlled metabolic wards — neither generalises confidently to free-living adults. EFSA explicitly classifies boron as non-essential because no boron-dependent biochemical pathway has been identified in humans, and EFSA derived no Dietary Reference Value EFSA 2004. The arthritis evidence is dominated by calcium-fructoborate trials funded by the patent holder; the only independent trial (Travers 1990) is itself underpowered. The VITAL cohort failed to replicate Cui's prostate-cancer signal. The cognitive evidence is a depletion-recovery finding (boron deprivation impairs cognition, restoring typical intake reverses it) — it does not show that supplementation above a varied diet adds anything. Typical Western diets already supply 1–2 mg/day; for most readers there is no deficit to fix.

Author's call

A modest, low-cost, low-risk supplement with credible — but pilot-grade — evidence on four genuine consequences: bone mineral retention (best supported), joint symptom relief in osteoarthritis (clinically meaningful, replicated across forms), sex-hormone modulation in men (small absolute effect, single tiny study), and short-term inflammation reduction (replicated, small trials). Cognition is a repletion-only effect that does not warrant a supplementation pitch for adults eating ordinarily. The article should lean cautiously positive — recommend 3–6 mg/day for adults with osteoarthritis, osteopenia/osteoporosis risk, or low-fruit-and-vegetable intake; honest about effect-size modesty and trial-size limitations; explicit that this is not a testosterone booster in the TRT sense. evidence: 3 (small RCTs, plausible mechanism, replicated direction across forms, no Cochrane-level data). controversy: 3 (active debate over essentiality, hormone-effect magnitude, calcium fructoborate trial industry funding; EFSA-vs-functional-medicine framing divides the field).

4. Stakeholder + incentive map

USDA Grand Forks Human Nutrition Research Center (Nielsen, Hunt, Penland) — federally funded research group that built the boron evidence base in the 1980s–2010s. No commercial conflict; outputs are conservative and mechanism-focused.
FutureCeuticals / VDF — patent holders for calcium fructoborate (FruiteX-B). Fund the calcium-fructoborate arthritis trials; the most cited recent clinical data has industry sponsorship. Findings are directionally consistent with non-industry research but should not be the sole evidence cited.
Functional / integrative medicine community (Pizzorno, Newnham, Stanfield) — strong proponents; the "Nothing Boring About Boron" review is the canonical advocacy text. Conservative interpretation appropriate.
EFSA, IOM, US ODS — official regulators classify boron as non-essential, set ULs but no RDA. Skeptical-but-permissive default.
Supplement industry (testosterone-booster segment) — frequently overstates the Naghii 28% free-T finding; the article should preempt this framing.
Counter / debunkers — mainstream endocrinology and clinical nutrition largely ignore boron rather than refute it; absence of high-quality RCTs is the most-cited objection.

5. Population variability

Postmenopausal women — strongest documented response on bone-mineral retention and steroid metabolism (foundational Grand Forks studies) Nielsen et al. 1987 Hunt et al. 1997. Effect amplified by concurrent low magnesium intake.
Men with osteoarthritis (mid-50s+) — primary cohort in calcium-fructoborate trials Scorei et al. 2011 Reyes-Izquierdo et al. 2012.
Geographic baseline. Habitual intake varies an order of magnitude across populations (0.5–1 mg/day in low-boron regions; 8–10 mg/day in parts of Turkey, Israel, parts of the US with high-boron groundwater) Pizzorno 2015. Supplementation response is largest at low baseline.
Dietary pattern. Coffee, raisins, dried fruits, nuts, avocados, and wine are the top dietary sources. Low-fruit, low-vegetable, low-coffee eaters are the likely responders.
Magnesium status. Bone and hormone effects in Nielsen 1987 were larger under low-magnesium conditions Nielsen et al. 1987. Boron may partially compensate for marginal magnesium intake.
Vitamin D status. Boron raises serum 25(OH)D₃ more in vitamin D-insufficient subjects than in replete subjects Pizzorno 2015.
Young, healthy, well-fed adults. The marginal benefit is smallest here — the population least likely to perceive a felt change.

6. Knowledge gaps

No long-duration RCT with hard endpoints. No 12–24-month boron supplementation trial with DXA bone-density, fracture incidence, or sustained hormonal endpoints. The entire bone-effect case is built on metabolic-ward calcium-balance studies.
Hormone-effect replication. The Naghii 2011 finding (n = 8, free-T +28% on 10 mg/day) has not been independently replicated in a larger cohort. Whether the effect persists past one week, whether it scales with baseline testosterone, and whether it has clinically meaningful downstream consequences (muscle mass, mood, libido) are unanswered.
Independent calcium-fructoborate trials. Most positive arthritis trials are funded by the patent holder; an industry-independent replication of the WOMAC / hs-CRP effect would substantially raise the evidence rating.
Optimal form and dose. Whether sodium tetraborate, boron glycinate, and calcium fructoborate produce equivalent effects at equivalent elemental-boron doses is poorly characterised. The plasma half-life argues for any-form-is-fine; the trial heterogeneity argues for keeping the question open.
What would change the call. A large, independent RCT (n > 500) of 6–10 mg/day boron over 12 months with DXA + symptom + inflammatory endpoints would either confirm a meaningful adjunct supplement or fold it into "trivial" status. A larger replication of Naghii's free-T finding would clarify the testosterone story. Mendelian-randomisation work on boron intake quartiles vs prostate cancer would clarify the Cui finding.

Scope vs brief. The brief named bone metabolism, joint health, sex hormone regulation, cognition, and inflammation. All five are covered. Cognition is honest-but-deflated: Penland's data is depletion-recovery, not enhancement, so the article frames it as "a low-fruit/low-veg eater may be running with a small handicap they would not otherwise notice" rather than a focus-improvement pitch. That tension also drives the focus: 1 score — non-zero because the literature supports a real cognitive deficit at deprivation, but not high enough to suggest healthy adults will sharpen up.

Hormones — scored as longevity / beauty_cumulative rather than its own dimension. The hormone-modulation story rides on a single n=8 study (Naghii 2011) and a single n=12 study (Nielsen 1987). The free-testosterone delta is the most-quoted line on the internet about boron and the most over-sold. The article body covers it honestly and explicitly preempts the "natural testosterone booster" framing in misconceptions. The score it contributes to is downstream (bone retention, prostate cancer epi, slow aging trajectory), not a hormone-axis dimension of its own.

Calcium fructoborate trials are industry-funded. Most of the recent positive arthritis trials (Scorei 2011, Reyes-Izquierdo 2012) are funded by FutureCeuticals / VDF, the FruiteX-B patent holder. Cited in the dossier and the article, but the article does not lean on them as primary evidence — Travers 1990 (independent, but tiny) does that work. The evidence score of 3 reflects this funding-quality discount.

Rating difficulties. evidence: 3 was the hardest call — directionally consistent across four mechanism families, but no Cochrane review, no long-duration hard-endpoint RCT, several positive trials industry-funded. A 2 would have under-rated the mechanistic coherence and replicated direction; a 4 would have implied guideline-grade evidence that does not exist. controversy: 3 reflects the EFSA-non-essential vs functional-medicine-routine-supplement gap, plus active lay debate over hormone-effect magnitude.

Beauty_cumulative scored 1, not 0. Bone-density retention in postmenopausal women has a real downstream contribution to long-term facial structure (jaw, cheekbones), and the foundational data is direct on the bone side. Going to 0 would have lost that thread; going to 2 would have overclaimed against the absence of any aesthetic-endpoint trial.

Contraindications. Pregnancy and breastfeeding are anchored to EFSA's UL derivation against rat developmental endpoints — the human-relevant data is thinner than the tag implies, but the conservative call matches regulatory guidance. Kidney-disease is the standard renal-excretion caution. Hormone-sensitive cancer is raised in-article but not formally tagged — there is no closed token for it in the schema, and the data does not justify a hard contraindication, only clinician consultation.

Out-of-scope. Boron pharmaceuticals (bortezomib, tavaborole) and boron neutron capture therapy are explicitly out of the supplement-scope. Industrial/occupational exposure (mining, glass manufacturing) is a toxicology question covered by EFSA and OSHA, not a supplementation question.

Future-link candidates. magnesium (the strongest co-actor — boron effects amplify under low-Mg conditions), vitamin-d (boron extends 25(OH)D half-life), resistance-training (the dominant bone-density intervention this article calls out as the real answer), and the wider Mediterranean-diet entry. Also a future calcium-fructoborate entry if the joint-health evidence base deepens.

Separate-entry candidates. A standalone calcium fructoborate for osteoarthritis entry could earn its keep if independent replication arrives. Boron-rich-water population epidemiology (Turkey, Israel) is interesting but does not warrant its own entry — it lives as context here.